FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,063 letters match. Newest first.

  1. Excelvision Fareva

    Excelvision Fareva, a sterile drug manufacturer, was cited for inadequate mold/black-speck complaint investigations and aseptic contamination controls.

    High risk
  2. Ningbo Riway Industrial Co., Ltd.

    Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.

    High risk
  3. OSRX, Inc.

    OSRX, a Montana compounding facility, made sterile ophthalmic drugs under insanitary conditions with quality and labeling failures.

    High risk
  4. Mentha & Allied Products Private Ltd.

    FDA warns Mentha & Allied Products of CGMP failures that leave its APIs adulterated.

    High risk
  5. Shantou S.E.Z. Baojie Industry Co., Ltd.

    FDA warns Shantou S.E.Z. Baojie Industry over inadequate CGMP and component testing for OTC drug products, leading to Import Alert 66-40.

    High risk
  6. Tailstorm Health Inc. dba Medivant Health

    Tailstorm Health (Medivant Health) sterile compounded drugs had insanitary conditions and current good manufacturing practice failures, prompting a bevacizumab recall.

    High risk
  7. Taizhou Jingshang Cosmetics Technology Co., Ltd.

    FDA warns Taizhou Jingshang Cosmetics Technology over current good manufacturing practice failures in over-the-counter drugs, including missing identity tests for high-risk ingredients.

    High risk
  8. Country Favor Inc.

    Country Favor Inc. had no foreign supplier verification program for imported foods, FDA found.

    Medium
  9. Cosco International, Inc.

    FDA warned Cosco International over nonprescription drug manufacturing failures and unapproved drug products.

    High risk
  10. Dyno Manufacturing, Inc.

    Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.

    High risk
  11. BEO Pharma Inc. dba BEO Pharmaceuticals Inc.

    FDA cited BEO Pharma for manufacturing quality violations, including missing identity testing of high-risk drug ingredients and releasing a batch before microbial testing.

    High risk
  12. Prodose, Inc. formerly known as Spirit Pharmaceuticals LLC

    Prodose, formerly Spirit Pharmaceuticals, left a cold and flu drug mislisted; FDA calls it misbranded.

    Low
  13. Livestock Nutrition Center

    Livestock Nutrition Center made non-medicated animal feed contaminated with monensin, killing animals; FDA found preventive control failures.

    High risk
  14. Empower Clinic Services, LLC dba Empower Pharma

    FDA warns Empower Pharma over sterile drug manufacturing deficiencies, labeling, and unapproved compounded drugs after August 2024 inspection.

    High risk
  15. Nubratori, Inc. dba Nubratori Rx

    FDA cited Nubratori Rx, a sterile compounding outsourcing facility, for insanitary conditions and manufacturing quality failures that may contaminate its drug products.

    High risk
  16. Annovex Pharma, Inc.

    FDA warns outsourcing facility Annovex Pharma in Lorton, VA, over contaminated sterile drug production and missed FDA reports.

    High risk
  17. Aspen Biopharma Labs Private Limited

    FDA warns Aspen Biopharma Labs over current good manufacturing practice failures in active ingredient manufacturing after U.S. recall.

    High risk
  18. Hangzhou Glamcos Biotech Co., Ltd.

    Hangzhou Glamcos Biotech’s OTC antibacterial wipes had CGMP violations and were unapproved and misbranded, FDA says.

    High risk
  19. Advanced Pharmaceutical Technology

    FDA warns Advanced Pharmaceutical Technology over drug manufacturing quality failures, sterility controls, and unapproved drugs.

    High risk
  20. Neva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi

    FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.

    High risk
  21. Kabana Skin Care

    FDA warned Kabana Skin Care that its "Kabana Body Wash +UV" is an unapproved, misbranded sunscreen drug sold without required FDA clearance.

    Medium
  22. Waxhead Sun Defense Company

    FDA warned Waxhead Sun Defense Company that its zinc body wash/shampoo is an unapproved, misbranded OTC sunscreen drug.

    Medium
  23. CoLabs Intl. Corp

    CoLabs Intl. Corp marketed KLĒNSKIN WASH ON SUNSCREEN, an OTC sunscreen wash, without an FDA-approved application or authorized dosage form.

    Medium
  24. Aspen Pharmacare Holdings Limited

    FDA warns Aspen subsidiary over sterile OTC drug manufacturing failures including impurity testing, aseptic practices, data integrity, and environmental monitoring.

    High risk
  25. Rite-Kem Incorporated

    FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.

    High risk
  26. Vegewax Candleworx Ltd.

    FDA warns Vegewax Candleworx over CGMP violations in OTC drug manufacturing, including inadequate component testing and OOS investigations.

    High risk
  27. Shree Jaya Laboratories PVT. LTD.

    FDA warned Shree Jaya Laboratories after an inspection found CGMP deviations in API and intermediate manufacturing, including dirty equipment and torn batch records.

    High risk
  28. Linghai ZhanWang Biotechnology Co., Ltd

    Linghai ZhanWang Biotechnology's OTC drugs, including antimicrobial wipes, fail manufacturing quality rules; FDA cites missing tests.

    High risk
  29. Right Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals

    FDA warned outsourcing facility Carie Boyd Pharmaceuticals in Irving, TX that sterile drug production had airflow, media fill and contamination control failures.

    High risk
  30. ProRx, LLC

    FDA warns ProRx, LLC about insanitary sterile compounded-drug production and manufacturing-quality failures.

    High risk
  31. Granules India Limited

    FDA warned Granules India in Telangana, India, that its finished drugs are adulterated after inspectors found cross-contamination in air ducts, bird droppings and torn records.

    High risk
  32. Chem-Tech, Ltd.

    Chem-Tech, Ltd. lacked adequate investigations and clean equipment for its OTC drug.

    High risk
  33. Garcia Fresh Vegetables LLC

    FDA warned Garcia Fresh Vegetables for lacking a Foreign Supplier Verification Program for all imported foods after a December 2024 inspection.

    Medium
  34. Radhaswamy Inc. dba Raja Foods LLC

    FDA warned Radhaswamy Inc. dba Raja Foods that it lacked required foreign supplier verification for most imported foods, including rice and candy.

    High risk
  35. ABR Laboratory LLC

    FDA warned ABR Laboratory, a contract drug testing lab, that unverified microbial test methods and missed investigations made tested drugs adulterated.

    High risk
  36. Tyche Industries Ltd

    FDA warned Tyche Industries over falsified records, dirty equipment, and untested raw materials at its API plant.

    High risk
  37. AmWiner & Raphe Holdings, LLC dba rapheGenerics Corp

    FDA cited rapheGenerics for manufacturing-quality failures and unapproved minoxidil hair regrowth drugs.

    High risk
  38. Strukmyer LLC dba Strukmyer Medical

    Strukmyer Medical was cited for current good manufacturing practice violations after FDA found repeated microbial contamination in water used to make OTC drugs.

    High risk
  39. Shantou Kangjie Daily Chemical Industry Co., Ltd

    FDA warns Shantou Kangjie over CGMP failures for OTC drugs, including untested ethanol and no quality unit.

    High risk
  40. Imperial Palace Commodity -Dongguan- Co., Ltd.

    FDA warns Chinese maker of OTC alcohol wipes that weak component testing and process validation make its drugs adulterated.

    High risk
  41. BioStem Life Sciences

    FDA says BioStem Life Sciences made unapproved umbilical cord and amniotic products with significant CGMP violations.

    High risk
  42. Global Calcium Pvt. Limited

    FDA cites Global Calcium API plant for falsified records, deleted files, facility leaks and incomplete impurity profiles; products on Import Alert 66-40.

    High risk
  43. Talla Imports, LLC

    FDA says Talla Imports lacked required foreign supplier safety plans for Swedish toffee, cookies and candy.

    Medium
  44. Fagron Compounding Services, LLC dba Fagron Sterile Service

    FDA warns Fagron Sterile Services about unsafe sterile drug production and labeling problems at its Wichita facility.

    High risk
  45. Kardesler Ucan Yaglar Sanayi Anonim Sirketi

    Turkey-based OTC drug maker Kardesler Ucan failed to test glycerin, propylene glycol and ethanol for dangerous impurities and is on US import alert.

    High risk
  46. Sanofi

    FDA warned Sanofi subsidiary Genzyme over manufacturing quality failures at its Framingham, MA API plant.

    High risk
  47. www.weightcrunchshop.com

    FDA warned www.weightcrunchshop.com about selling unapproved and misbranded semaglutide and oxycodone drugs to U.S. consumers online.

    High risk
  48. Atlanta Supersource, Inc.

    Atlanta Supersource made OTC hand sanitizers on equipment shared with toxic industrial chemicals and lacked testing, FDA says.

    High risk
  49. Premium Fresh Growers LLC

    FDA warns Premium Fresh Growers it lacked required foreign supplier checks for imported limes, cilantro, and carrots.

    Medium
  50. Western Innovations, Inc.

    FDA warns Western Innovations over manufacturing-rule violations in Acetyl-glutathione supplements after Denver inspection.

    Medium